ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2013
Delayed anti-CD3 therapy results in depletion of alloreactive T cells and the dominance of Foxp3+ CD4+ graft infiltrating cells.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes.European journal of immunology · 2016Trial
- TCF1highPD-1+Ly108+CD8+ T Cells Are Associated with Graft Preservation in Sensitized Mice Treated with Non-Fc Receptor-Binding CD3 Antibodies.ImmunoHorizons · 2024Article
- Modulating T Cell Responses by Targeting CD3.Cancers · 2023Review
- Reduced Satb1 expression predisposes CD4Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Cellular Mechanisms of Rejection of Optic and Sciatic Nerve Transplants: An Observational Study.Transplantation direct · 2020Article
- Targeted delivery of immune therapeutics to lymph nodes prolongs cardiac allograft survival.The Journal of clinical investigation · 2018Article
- Functional Defects of Treg Cells: New Targets in Rheumatic Diseases, Including Ankylosing Spondylitis.Current rheumatology reports · 2018Review
- Evolving Approaches in the Identification of Allograft-Reactive T and B Cells in Mice and Humans.Transplantation · 2017Review
- Delayed and short course of rapamycin prevents organ rejection after allogeneic liver transplantation in rats.World journal of gastroenterology · 2017Article
- Article
- The Induction and Maintenance of Transplant Tolerance Engages Both Regulatory and Anergic CD4Frontiers in immunology · 2017Article
- Age-related Defects in Ocular and Nasal Mucosal Immune System and the Immunopathology of Dry Eye Disease.Ocular immunology and inflammation · 2016Review
- TGFβ-dependent expression of PD-1 and PD-L1 controls CD8(+) T cell anergy in transplant tolerance.eLife · 2016Article
- Targeting Treg signaling for the treatment of autoimmune diseases.Current opinion in immunology · 2015Review
- Differential sensitivity of regulatory and effector T cells to cell death: a prerequisite for transplant tolerance.Frontiers in immunology · 2015Review
- Tolerogenic Dendritic Cells on Transplantation: Immunotherapy Based on Second Signal Blockage.Journal of immunology research · 2015Review
- Lung transplantation: chronic allograft dysfunction and establishing immune tolerance.Human immunology · 2014Review
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
The engineered Fc-nonbinding (crystallizable fragment-nonbinding) CD3 antibody has lower mitogenicity and a precise therapeutic window for disease remission in patients with type 1 diabetes. Before anti-CD3 can be considered for use in transplantation, the most effective timing of treatment relative to transplantation needs to be elucidated. In this study anti-CD3F(ab')2 fragments or saline were administered intravenously for 5 consecutive days (early: d1-3 or delayed: d3-7) to mice transplanted with a cardiac allograft (H2(b)-to-H2(k); d0). Survival of allografts was prolonged in mice treated with the early protocol (MST = 48 days), but most were rejected by d100. In contrast, in mice treated with the delayed protocol allografts continued to survive long term. The delayed protocol significantly inhibited donor alloreactivity at d30 as compared to the early protocol. A marked increase in Foxp3(+) T cells (50.3 ± 1.6%) infiltrating the allografts in mice treated with the delayed protocol was observed (p < 0.0001 vs. early (24.9 ± 2.1%)) at d10; a finding that was maintained in the accepted cardiac allografts at d100. We conclude that the timing of treatment with anti-CD3 therapy is critical for inducing long-term graft survival. Delaying administration effectively inhibits the alloreactivity and promotes the dominance of intragraft Foxp3(+) T cells allowing long-term graft acceptance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.